Armistice Capital, LLC Voyager Therapeutics, Inc. Transaction History

Armistice Capital, LLC

$6.56 Billion
Q1 2025

A detailed history of Armistice Capital, LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 5,436,000 shares of VYGR stock, worth $17.5 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

5,436,000

Previous 5,396,000 0.74%

Holding current value

$17.5 Million

Previous $30.6 Million 39.95%

% of portfolio

0.28%

Previous 0.43%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$3.38 - $6.04 $135,200 - $241,600	40,000 Added 0.74%	5,436,000 $18.4 Million
Q4 2024 Feb 14, 2025	BUY	$5.27 - $8.07 $1.03 Million - $1.58 Million	196,000 Added 3.77%	5,396,000 $30.6 Million
Q2 2024 Aug 14, 2024	BUY	$7.42 - $10.54 $3.92 Million - $5.57 Million	528,000 Added 11.3%	5,200,000 $41.1 Million
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $3.12 Million - $4.73 Million	436,000 Added 10.29%	4,672,000 $43.5 Million
Q4 2023 Feb 13, 2024	BUY	$6.28 - $8.81 $364,240 - $510,980	58,000 Added 1.39%	4,236,000 $35.8 Million
Q3 2023 Nov 14, 2023	BUY	$7.55 - $11.25 $4.18 Million - $6.23 Million	554,000 Added 15.29%	4,178,000 $32.4 Million
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $694,000 - $1.4 Million	100,000 Added 2.84%	3,624,000 $41.5 Million
Q1 2023 May 15, 2023	BUY	$6.0 - $10.78 $768,000 - $1.38 Million	128,000 Added 3.77%	3,524,000 $27.2 Million
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $4.63 Million - $6.22 Million	832,000 Added 32.45%	3,396,000 $20.1 Million
Q2 2022 Aug 15, 2022	BUY	$4.82 - $10.09 $2.72 Million - $5.69 Million	564,000 Added 28.2%	2,564,000 $15.2 Million
Q1 2022 May 16, 2022	BUY	$2.75 - $9.44 $5.5 Million - $18.9 Million	2,000,000 New	2,000,000 $15.2 Million
Q4 2021 Feb 14, 2022	SELL	$2.47 - $5.55 $9.18 Million - $20.6 Million	-3,716,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.61 - $9.04 $1.49 Million - $2.93 Million	324,000 Added 9.55%	3,716,000 $17.5 Million
Q4 2020 Feb 16, 2021	BUY	$7.15 - $12.28 $4.95 Million - $8.5 Million	692,000 Added 25.63%	3,392,000 $24.3 Million
Q3 2020 Nov 16, 2020	BUY	$10.01 - $13.75 $6.23 Million - $8.55 Million	622,000 Added 29.93%	2,700,000 $28.8 Million
Q2 2020 Aug 14, 2020	SELL	$8.05 - $14.21 $1.27 Million - $2.25 Million	-158,000 Reduced 7.07%	2,078,000 $26.2 Million
Q1 2020 May 15, 2020	BUY	$6.8 - $14.66 $4.16 Million - $8.97 Million	612,000 Added 37.68%	2,236,000 $20.5 Million
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $6.77 Million - $8.9 Million	528,000 Added 48.18%	1,624,000 $22.7 Million
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $2.61 Million - $4.53 Million	160,000 Added 17.09%	1,096,000 $18.9 Million
Q2 2019 Aug 14, 2019	SELL	$19.18 - $27.88 $11.5 Million - $16.7 Million	-600,000 Reduced 39.06%	936,000 $25.5 Million
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $10.4 Million - $25.6 Million	-1,300,000 Reduced 45.84%	1,536,000 $29.4 Million
Q4 2018 Feb 14, 2019	BUY	$8.59 - $18.05 $9.55 Million - $20.1 Million	1,112,000 Added 64.5%	2,836,000 $26.7 Million
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $22.1 Million - $28.1 Million	1,292,000 Added 299.07%	1,724,000 $32.6 Million
Q2 2018 Aug 14, 2018	BUY	$16.76 - $23.92 $7.24 Million - $10.3 Million	432,000 New	432,000 $8.44 Million

Others Institutions Holding VYGR

# of Institutions

119

Shares Held

34.5M

Call Options Held

12.9K

Put Options Held

37.7K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $124M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Voyager Therapeutics, Inc. Transaction History